Advances in HBV infection and replication systems in vitro

Xu, Ruirui; Hu, Pingping; Li, Yuwen; Tian, Anran; Li, Jun; Zhu, Chuanlong

doi:10.1186/s12985-021-01580-6

Cited by 24 publications

(24 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficiency of in vitro HBV replication will be considered acceptable if the amount of DNA will reach 10±7x10 5 viral copies/mL of the supernatant during the cultivation period [ 63 ].…”

Section: Discussionmentioning

confidence: 99%

Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts

et al. 2022

View full text Add to dashboard Cite

Background According to the World Health Organization, more than 250 million people worldwide are chronically infected with the hepatitis B virus, and almost 800.000 patients die annually of mediated liver disorders. Therefore, adequate biological test systems are needed that could fully simulate the course of chronic hepatitis B virus infection, including in patients with hepatocellular carcinoma. Methods In this study, we will assess the effectiveness of existing protocols for isolation and cultivation of primary cells derived from patients with hepatocellular carcinoma in terms of the yield of viable cells and their ability to replicate the hepatitis B virus using isolation and cultivation methods for adhesive primary cells, flow cytometry and quantitative polymerase chain reaction. Another part of our study will be devoted to evaluating the effectiveness of hepatocellular carcinoma grafting methods to obtain patient-derived heterotopic and orthotopic xenograft mouse avatars using animal X-ray irradiation and surgery procedures and in vivo fluorescent signals visualization and measurements. Our study will be completed by histological methods. Discussion This will be the first extensive comparative study of the main modern methods and protocols for isolation and cultivation primary hepatocellular carcinoma cells and tumor engraftment to the mice. All protocols will be optimized and characterized using the: (1) efficiency of the method for isolation cells from removed hepatocellular carcinoma in terms of their quantity and viability; (2) efficiency of the primary cell cultivation protocol in terms of the rate of monolayer formation and hepatitis B virus replication; (3) efficiency of the grafting method in terms of the growth rate and the possibility of hepatitis B virus persistence and replication in mice. The most effective methods will be recommended for use in translational biomedical research.

show abstract

Section: Discussionmentioning

confidence: 99%

Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts

et al. 2022

View full text Add to dashboard Cite

show abstract

“…HBV is one of the smallest viruses with a genome length of 3.2 Kb [34]. Its genome contains four open reading frames (ORFs) coding four partially overlapping proteins as displayed in Figure 1: (1) preS/S ORF encodes large (L), middle (M), and small (S) surface antigens (HBsAg).…”

Section: Hbv Proteome and The Approaches Identifying T Cell Epitopesmentioning

confidence: 99%

A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus

Ding

Shen

2022

Vaccines

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection remains a worldwide health problem and no eradicative therapy is currently available. Host T cell immune responses have crucial influences on the outcome of HBV infection, however the development of therapeutic vaccines, T cell therapies and the clinical evaluation of HBV-specific T cell responses are hampered markedly by the lack of validated T cell epitopes. This review presented a map of T cell epitopes functionally validated from HBV antigens during the past 33 years; the human leukocyte antigen (HLA) supertypes to present these epitopes, and the methods to screen and identify T cell epitopes. To the best of our knowledge, a total of 205 CD8+ T cell epitopes and 79 CD4+ T cell epitopes have been defined from HBV antigens by cellular functional experiments thus far, but most are restricted to several common HLA supertypes, such as HLA-A0201, A2402, B0702, DR04, and DR12 molecules. Therefore, the currently defined T cell epitope repertoire cannot cover the major populations with HLA diversity in an indicated geographic region. More researches are needed to dissect a more comprehensive map of T cell epitopes, which covers overall HBV proteome and global patients.

show abstract

“…78,79 For instance, the HBVinduced liver disease could theoretically be corrected by transplantation with HBV receptor (NTCP) knock-out or ectopic expression of NTCP variants in HLCs derived from edited PSCs. 80,81 Following transplantation in such patients, HBV could not enter hepatocytes as they lacked the receptor, which would avoiding the recurrence of HBV. Treatment might thus be adjusted depending on the pathophysiology of the primary illness that caused ALF.…”

Section: Transplantation Feasibility and Safetymentioning

confidence: 99%

Pluripotent Stem Cell-derived Strategies to Treat Acute Liver Failure: Current Status and Future Directions

Liu¹,

Yuan²,

Wang³

2022

J Clin Transl Hepatol

View full text Add to dashboard Cite

Liver disease has long been a heavy health and economic burden worldwide. Once the disease is out of control and progresses to end-stage or acute organ failure, orthotopic liver transplantation (OLT) is the only therapeutic alternative, and it requires appropriate donors and aggressive administration of immunosuppressive drugs. Therefore, hepatocyte transplantation (HT) and bioartificial livers (BALs) have been proposed as effective treatments for acute liver failure (ALF) in clinics. Although human primary hepatocytes (PHs) are an ideal cell source to support these methods, the large demand and superior viability of PH is needed, which restrains its wide usage. Thus, a finding alternative to meet the quantity and quality of hepatocytes is urgent. In this context, human pluripotent stem cells (PSC), which have unlimited proliferative and differential potential, derived hepatocytes are a promising renewable cell source. Recent studies of the differentiation of PSC into hepatocytes has provided evidence that supports their clinical application. In this review, we discuss the recent status and future directions of the potential use of PSC-derived hepatocytes in treating ALF. We also discuss opportunities and challenges of how to promote such strategies in the common applications in clinical treatments.

show abstract

Advances in HBV infection and replication systems in vitro

Cited by 24 publications

References 99 publications

Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts

Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts

A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus

Pluripotent Stem Cell-derived Strategies to Treat Acute Liver Failure: Current Status and Future Directions

Contact Info

Product

Resources

About